Drugs / Quinine
Quinine
also known as
Quinine Sulfate · GLS-1200 · Quinine Hydrochloride · (8s,9r)-6'-methoxycinchonan-9-ol · Acid quinine hydrochloride · Anhydrous quinine hydrobromide · Anhydrous quinine hydrochloride · Anhydrous quinine sulfate · +45 more
Small molecule targets CYP2C8 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | QUALAQUIN | — | 2005-08-12 | fda.gov ↗ |
Trials 30 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04873011 | Oct 2020 → Oct 2025 overdue | obesity disorder | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 1 | NCT02598713 | Dec 2015 → Jun 2024 | pneumonia | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT01851473 | Oct 2012 → Oct 2015 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00785980 | Sep → Oct 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00785213 | Sep → Oct 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00785551 | Nov 2007 → Jan 2011 | impaired renal function disease | Mutual Pharmaceutical Company, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00779259 | Aug → Sep 2007 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00806078 | Jul → Aug 2007 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00785486 | Mar 2007 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00726414 | Dec 2005 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00726895 | May → Jun 2004 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00727272 | Feb → Mar 2004 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02630472 | Oct 2015 → May 2017 | rhinitis, sinusitis | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07572396 | Apr → Dec 2026 expected | cervix disorder, dysplasia of cervix, human papilloma virus infection, squamous cell intraepithelial neoplasia | Amplexd Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04060316 | Dec 2023 | chronic rhinosinusitis | GeneOne Life Science, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04408183 | Jun 2020 → Jan 2023 | COVID-19 | GeneOne Life Science, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02276989 | Dec 2014 → Jan 2016 | chronic pain syndrome | Georgetown University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00329134 | Jul 2006 → May 2007 | Plasmodium falciparum malaria | University Ghent | Completed | No outcome recorded |
| Phase 2 | NCT00322907 | Apr 2000 → Jan 2003 | malaria | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | Terminated | No outcome recorded |
| Phase 2 | NCT00299208 | ? → Jul 2005 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04553705 | Sep → Nov 2020 | COVID-19, immunodeficiency disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00124267 | Sep 2003 → Jan 2004 | cerebral malaria | Makerere University | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03985865 | Mar 2017 → May 2018 | obesity disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01805232 | Mar → May 2013 | malaria | University of Khartoum | Unknown | No outcome recorded |
| Phase 4 | NCT00540202 | Sep 2007 → Apr 2008 | malaria | Makerere University | Unknown | No outcome recorded |
| Phase 4 | NCT00167739 | Apr 2003 → Feb 2004 | malaria | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00451139 | — | malaria | Jimma University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06472258 | Mar → Jun 2023 | malaria | RESnTEC, Institute of Research | Completed | No outcome recorded |
| — | NCT05808231 | Apr 2021 → Jun 2022 | COVID-19 | Padjadjaran University | Unknown | No outcome recorded |
| — | NCT00000706 | ? → Dec 1988 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 11 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02492178 Background | Jul → Oct 2015 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01047436 Comparator | Dec 2009 → Jan 2010 | Plasmodium falciparum malaria | Proto Pharma Ltd | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02563704 Comparator | Sep 2013 → Mar 2014 | malaria | University of Yaounde 1 | Completed | No outcome recorded |
| Phase 3 | NCT02974348 Background | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT01374581 Comparator | May 2012 → Jun 2014 | malaria | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT01258049 Comparator | Dec 2010 → Aug 2012 | Plasmodium falciparum malaria | Proto Pharma Ltd | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02092766 Comparator | Jun 2014 → Apr 2015 | anemia | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00495508 Comparator | Oct 2006 → Jun 2009 | Plasmodium falciparum malaria | Epicentre | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04093765 Background | Nov 2018 → Dec 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT02759926 Comparator | Aug 2011 → Nov 2015 | obesity disorder | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| — | NCT00639873 Comparator | Jun 2008 → Nov 2009 | malaria | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 58 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quinine | “Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.” NCT02598713 ↗29“Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).” NCT04093765 ↗ |
| Known as | (8s,9r)-6'-methoxycinchonan-9-ol | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Acid quinine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Anhydrous quinine hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Anhydrous quinine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Anhydrous quinine sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Chininum muriaticum | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Chininum purum | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Chininum sulphuricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | FEMA NO. 2976 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | FEMA NO. 2976, DIHYDRATE- | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | FEMA NO. 2977 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | GLS-1200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04060316 ↗ |
| Known as | Neutral quinine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | NSC-192949 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | NSC-5362 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | NSC-757298 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Qualaquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Qualaquin, Quinine Sulfate | “Qualaquin, Quinine Sulfate” NCT00785486 ↗ |
| Known as | Quinamm | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine biascorbate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine bimuriate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | QUININE DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hbr | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hemisulfate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | QUININE HYDROBROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hydrobromide anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hydrobromide monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06472258 ↗ |
| Known as | Quinine hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine muriate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | QUININE PHOSPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine phosphate, anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine Sulfate | “Quinine Sulfate 324 mg Capsules” NCT00785213 ↗ |
| Known as | Quinine sulfate (2:1) | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine sulfate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine sulfate dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine sulfate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, monohbr | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, monohydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, monosalicylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, phosphate (3:2) (salt) | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, sulfate (1:1) (salt) | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinine, sulfate (2:1) (salt) | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinini dihydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Quinini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | Rezquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Known as | WR297608 | ChEMBL registry synonym — accepted as the source's own label CHEMBL170 ↗ |
| Action | Activate | “quinine was shown to induce the activity of Cytochrome p450 CYP 1A2.” NCT00779259 ↗ |
| Modality | Small molecule | — CHEMBL170 ↗ |
| Route | Rectal | “Intrarectal quinine (15mg/kg every 8 hours)” NCT00124267 ↗ |
| Target | CYP2C8 | “Quinine sulfate is an inhibitor of CYP 2C8.” NCT00785213 ↗ |